PYFA Stock Overview
Engages in the development, production, and trading of pharmaceuticals primarily in Indonesia.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
PT Pyridam Farma Tbk Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | Rp100.00 |
52 Week High | Rp1,545.00 |
52 Week Low | Rp81.00 |
Beta | 0.81 |
11 Month Change | -9.09% |
3 Month Change | -0.99% |
1 Year Change | -86.93% |
33 Year Change | -91.30% |
5 Year Change | -45.65% |
Change since IPO | -64.29% |
Recent News & Updates
Recent updates
Shareholder Returns
PYFA | ID Pharmaceuticals | ID Market | |
---|---|---|---|
7D | -2.9% | 0.4% | -1.2% |
1Y | -86.9% | -18.1% | 9.4% |
Return vs Industry: PYFA underperformed the ID Pharmaceuticals industry which returned -18.1% over the past year.
Return vs Market: PYFA underperformed the ID Market which returned 9.4% over the past year.
Price Volatility
PYFA volatility | |
---|---|
PYFA Average Weekly Movement | 9.5% |
Pharmaceuticals Industry Average Movement | 5.2% |
Market Average Movement | 5.8% |
10% most volatile stocks in ID Market | 12.8% |
10% least volatile stocks in ID Market | 2.9% |
Stable Share Price: PYFA's share price has been volatile over the past 3 months.
Volatility Over Time: PYFA's weekly volatility has decreased from 17% to 10% over the past year, but is still higher than 75% of ID stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1976 | 1,193 | Yan Gwan Lee | www.pyfa.co.id |
PT Pyridam Farma Tbk engages in the development, production, and trading of pharmaceuticals primarily in Indonesia. The company operates in two segments, Pharmaceutical Products, Esthetic, and Toll Manufacturing Services; and Medical Equipments. It supplies medical instruments and equipment, including clinical waste, collection swab, collection tube, innerbox DCA, KF94 mask, parafilm, PCR – extraction kit and extractor machine, speciment bag, sterile container, PCR machine- Gentier 48, and tube stopper.
PT Pyridam Farma Tbk Fundamentals Summary
PYFA fundamental statistics | |
---|---|
Market cap | Rp1.12t |
Earnings (TTM) | -Rp85.22b |
Revenue (TTM) | Rp702.07b |
1.6x
P/S Ratio-13.2x
P/E RatioIs PYFA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PYFA income statement (TTM) | |
---|---|
Revenue | Rp702.07b |
Cost of Revenue | Rp406.75b |
Gross Profit | Rp295.32b |
Other Expenses | Rp380.54b |
Earnings | -Rp85.22b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -7.58 |
Gross Margin | 42.06% |
Net Profit Margin | -12.14% |
Debt/Equity Ratio | 273.3% |
How did PYFA perform over the long term?
See historical performance and comparison